Find disease awareness content and relevant supporting materials

Background: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity.

This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody) compared with docetaxel...

The Phase III OAK study of Tecentriq (atezolimumab) from Genetech/Roche is the first randomised phase |III study to report results...

Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq...

The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years...

The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients...

Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy.

Genentech, announced positive results for Tecentriq from the Phase III study, OAK. The study met its co-primary endpoints and showed...

Genentech announced data from the positive, pivotal Phase III OAK study of Tecentriq (atezolizumab) which showed Tecentriq helped people live...

This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure.